Eli Lilly and Co (LLY)
731.88
-13.81
(-1.85%)
USD |
NYSE |
Apr 24, 16:00
724.60
-7.28
(-0.99%)
After-Hours: 20:00
Eli Lilly Revenue (TTM): 34.12B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 34.12B |
| September 30, 2023 | 32.07B |
| June 30, 2023 | 29.52B |
| March 31, 2023 | 27.69B |
| December 31, 2022 | 28.54B |
| September 30, 2022 | 29.24B |
| June 30, 2022 | 29.07B |
| March 31, 2022 | 29.32B |
| December 31, 2021 | 28.32B |
| September 30, 2021 | 27.76B |
| June 30, 2021 | 26.73B |
| March 31, 2021 | 25.49B |
| December 31, 2020 | 24.54B |
| September 30, 2020 | 23.21B |
| June 30, 2020 | 22.95B |
| March 31, 2020 | 23.09B |
| December 31, 2019 | 22.32B |
| September 30, 2019 | 21.84B |
| June 30, 2019 | 21.67B |
| March 31, 2019 | 21.62B |
| December 31, 2018 | 21.49B |
| September 30, 2018 | 19.12B |
| June 30, 2018 | 19.47B |
| March 31, 2018 | 19.71B |
| December 31, 2017 | 19.97B |
| Date | Value |
|---|---|
| September 30, 2017 | 22.47B |
| June 30, 2017 | 22.00B |
| March 31, 2017 | 21.59B |
| December 31, 2016 | 21.22B |
| September 30, 2016 | 20.84B |
| June 30, 2016 | 20.61B |
| March 31, 2016 | 20.18B |
| December 31, 2015 | 19.96B |
| September 30, 2015 | 19.70B |
| June 30, 2015 | 19.62B |
| March 31, 2015 | 19.58B |
| December 31, 2014 | 19.62B |
| September 30, 2014 | 20.30B |
| June 30, 2014 | 21.20B |
| March 31, 2014 | 22.19B |
| December 31, 2013 | 23.11B |
| September 30, 2013 | 23.26B |
| June 30, 2013 | 22.93B |
| March 31, 2013 | 22.60B |
| December 31, 2012 | 22.60B |
| September 30, 2012 | 22.69B |
| June 30, 2012 | 23.40B |
| March 31, 2012 | 24.05B |
| December 31, 2011 | 24.29B |
| September 30, 2011 | 24.43B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
21.67B
Minimum
Jun 2019
34.12B
Maximum
Dec 2023
26.71B
Average
27.69B
Median
Mar 2023
Revenue (TTM) Benchmarks
| Amgen Inc | 28.19B |
| Biogen Inc | 9.836B |
| Madrigal Pharmaceuticals Inc | -- |
| Vertex Pharmaceuticals Inc | 9.869B |
| Viking Therapeutics Inc | -- |